EASYGEN is a collaborative European public-private research project aiming to optimise CAR-T manufacturing hospital workflows, supporting more scalable access to advanced cell therapies and a sustainable healthcare workforce.
About EASYGEN
Today's CAR-T therapies have a median vein-to-vein time of 3 to 6 weeks. Dependence on specialized, central manufacturing facilities, laborious and cost-intensive workflows, and a complex logistics can limit timely access to these transformative therapies.
About ~30%A future where CAR-T therapies can be manufactured directly in hospitals, using automated, non-viral manufacturing approaches — bringing production closer to patients and helping make advanced cell therapies more accessible and scalable.
EASYGEN's (EASY Workflow Integration for GENe Therapy) mission is to help broaden access to advanced cell therapies through the development and evaluation of a scalable, automated, non-viral, point-of-care manufacturing platform that brings CAR-T production closer to the patient.
But technology alone is not enough. EASYGEN brings together manufacturing, quality control, digital integration, hospital workflows, health economics, regulatory considerations and patient perspectives to explore how decentralised CAR-T manufacturing could work in real healthcare environments.
Target a 50% reduction in treatment-related costs.
Reduce manufacturing time to under 24 hours.
Broaden access for more patients.
Embed decentralised manufacturing into routine hospital workflows.
EASYGEN brings together a multidisciplinary European public-private consortium spanning hospitals, academia, research organisations, technology providers, industry and patient organisations. Together, the partners contribute expertise across cell therapy, non-viral gene engineering, automated manufacturing, quality control, digital technologies, health economics, hospital implementation and patient engagement.
EASYGEN is coordinated by Fresenius SE & Co. KGaA,
with scientific co-leadership from Fraunhofer IZI.
